Medtronic has delivered four consecutive earnings beats on a foundation of near-perfect financial health metrics, but the stock is in a confirmed technical downtrend, options positioning signals unusual caution at a put/call ratio of roughly 5.7, and sole-source supplier dependencies represent a supply-chain vulnerability that limits conviction to add at current prices.
Thesis pillars
- Consistent Earnings Delivery→Stable
- Strong Financial Health Score→Stable
- Confirmed Technical Downtrend→Stable
- +2 more pillars — see the Why tab for full reasoning
Medtronic plc. (MDT) Stock Analysis
Recovery setup
Healthcare · Medical Devices
Hold if already holding. Not a fresh buy at $83.20, but acceptable to hold if already in. Reasons: Thin upside margin: 5.8%; Below 200-MA, MA slope -1.8%/30d (confirmed downtrend).
Medtronic designs, manufactures and sells medical devices and therapies across four segments - Cardiovascular, Neuroscience, Medical Surgical, and Diabetes - serving healthcare systems, physicians and patients in more than 150 countries. The company employs over 95,000 people,... Read more
Hold if already holding. Not a fresh buy at $83.20, but acceptable to hold if already in. Reasons: Thin upside margin: 5.8%; Below 200-MA, MA slope -1.8%/30d (confirmed downtrend). Chart setup: Death cross but MACD improving, RSI 60. Maintain position. Not compelling to add more. Score 5.7/10, moderate confidence.
Passes 6/9 gates (positive momentum, clean insider activity, no SEC red flags, earnings proximity 46d clear, semi cycle peak clear, materials cycle peak clear). Fails on favorable risk/reward ratio and death cross (50MA < 200MA). Suitability: moderate.
About Medtronic plc.
About Medtronic plc.
Medtronic plc develops and commercializes device-based medical therapies across four segments — Cardiovascular Portfolio, Neuroscience Portfolio, Medical Surgical Portfolio, and Diabetes Operating Unit — serving healthcare providers in more than 150 countries. Products span cardiac pacemakers (Micra VR, Azure), transcatheter aortic valves (Evolut PRO+, Evolut FX+), spinal navigation and robotics (Mazor systems, StealthStation S8), and the MiniMed 780G insulin pump system; 95,000+ full-time employees as of fiscal year 2025 support global operations, with 44% based in the U.S. or Puerto Rico.
Medtronic sells devices through hospitals, health systems, and physician practices, with revenue driven by capital equipment (surgical navigation systems, Mazor robotic guidance, Hugo robotic-assisted surgery), single-use consumables (pacemaker leads, ablation catheters, stapling reloads), and remote monitoring services. The Cardiovascular Portfolio covers cardiac rhythm management, structural heart (CoreValve Evolut family for TAVR, Harmony transcatheter pulmonary valves), and coronary and peripheral vascular devices. The Neuroscience Portfolio encompasses spinal robotics, neuromodulation (Intellis, Vanta, Inceptiv spinal cord stimulation; Percept family for Parkinson's disease and essential tremor), and neurovascular stroke treatment. Manufacturing depends on numerous global facilities and, for certain components, sole-source suppliers. Competition from pharmaceutical GLP-1 therapies poses a discrete threat to device utilization in metabolic indications. The Diabetes Operating Unit's MiniMed 780G and Guardian Connect CGM are subject to a planned spin-off announced in May 2025, targeted to complete within 18 months of that announcement.
Show full overview
Medtronic's 10-K explicitly discloses that certain components, raw materials, and services required for product manufacturing are obtained from sole suppliers, and that FDA and non-U.S. regulatory requirements limit how quickly alternate supply sources can be approved. Additionally, several key products are manufactured or sterilized at specific facilities with constrained capacity and limited alternate sterilization options — a single-site closure may result in an inability to manufacture or sterilize those products at all. EU MDR implementation deadlines — extended to end-2027 for high-risk devices and end-2028 for medium- and low-risk devices — add a concurrent compliance burden that may require significant expenditure across the product portfolio.
See also: Healthcare · Medical Devices
From Medtronic plc.'s most recent 10-K filing, extracted June 11, 2026.
Recent developments
updated 2026-07-06Recent Developments — Medtronic plc.
Latest news
- NEWS Can Medtronic (MDT) Close the Growth Gap With Its Bigger MedTech Rivals? - Yahoo Finance — Yahoo Finance neutral
- NEWS Can Medtronic (MDT) Close the Growth Gap With Its Bigger MedTech Rivals? - finance.yahoo.com — finance.yahoo.com positive
- NEWS Medtronic plc stock (IE00BTN1Y115): investors eye upcoming Q4 2026 earnings as options market prices - AD HOC NEWS — AD HOC NEWS neutral
- NEWS A Look at Medtronic PLC (MDT) After 3.9% Decline -- GF Value $99 - GuruFocus — GuruFocus negative
- NEWS Medtronic PLC stock underperforms Wednesday when compared to competitors - MarketWatch — MarketWatch negative
Generated 2026-07-06T06:00:35Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
1 floor-breaker
Technicals below the gate floor. Component breakdown shows what dragged the score down.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Hold if already holding. Not a fresh buy at $83.20, but acceptable to hold if already in. Reasons: Thin upside margin: 5.8%; Below 200-MA, MA slope -1.8%/30d (confirmed downtrend). Chart setup: Death cross but MACD improving, RSI 60. Maintain position. Not compelling to add more. Target $87.99 (+5.8%), stop $79.05 (−5.2%), A.R:R 0.8:1. Score 5.7/10, moderate confidence.
Take-profit target: $87.99 (+5.8% upside). Target $87.99 (+5.8%), stop $79.05 (−5.2%), A.R:R 0.8:1. Stop-loss: $79.05.
Thin upside margin: 5.8%; Below 200-MA, MA slope -1.8%/30d (confirmed downtrend).
Medtronic plc. trades at a P/E of 22.3 (forward 13.0). TrendMatrix value score: 6.4/10. Verdict: Hold.
37 analysts cover MDT with a consensus score of 3.8/5. Average price target: $98.
What does Medtronic plc. do?Medtronic designs, manufactures and sells medical devices and therapies across four segments - Cardiovascular,...
Medtronic designs, manufactures and sells medical devices and therapies across four segments - Cardiovascular, Neuroscience, Medical Surgical, and Diabetes - serving healthcare systems, physicians and patients in more than 150 countries. The company employs over 95,000 people, with 44% based in the U.S. or Puerto Rico, and in May 2025 announced plans to separate its Diabetes business into an independent public company within 18 months.